Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 5
Submit an article Journal homepage
1,494
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Focus on cardiometabolic risk factors

Patrizio Lancellottia Department of Cardiology, CHU SartTilman, University of Liège Hospital, GIGA Cardiovascular Sciences, Liège, Belgium;b Maria Cecilia Hospital, Cotignola, and Anthea Hospital, Gruppo Villa Maria Care and Research, Bari, ItalyCorrespondence[email protected]
Pages 515-518 | Published online: 17 Jul 2023

References

  • Jorissen W, Annemans L, Louis N, et al. Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with canagliflozin in Belgium. Acta Clin Belg. 2022;77(6):945–954. doi: 10.1080/17843286.2021.2015554.
  • Leiter LA, Fitchett DH, Gilbert RE, et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol. 2011;27(2):e1–e33. doi: 10.1016/j.cjca.2010.12.054.
  • Lancellotti P, Cosyns B. Highlights of acta cardiologica. Acta Cardiol. 2022;77(6):469–470. doi: 10.1080/00015385.2022.2143092.
  • Menotti A, Puddu PE, Catasta G. Lifestyle behaviors predicting major cardiovascular diseases mortality in a practically extinct cohort of Middle-aged men followed-up for 61 years. Acta Cardiol. 2023;78(5):578–585. doi: 10.1080/00015385.2022.2101876.
  • Ebrahimi H, Shayestefar M, Talebi SS, et al. Prevalence of hypertension and its associated factors among professional drivers: a population-based study. Acta Cardiol. 2023;78(5):543–551. doi: 10.1080/00015385.2022.2045753.
  • Stremmel C, Vdovin N, Kellnar A, et al. Impact of moderate altitude exposure on cardiovascular risk. Acta Cardiol. 2021;16:1–4. doi: 10.1080/00015385.2021.1976449.
  • Prosecky R, Kunzova S, Kovacovicova P, et al. Association of anthropometric and body composition parameters with the presence of hypertension in the central european population: results from KardioVize 2030 study. Acta Cardiol. 2023;78(5):614–622. doi: 10.1080/00015385.2023.2192153.
  • Humbert X, Licaj I, Fedrizzi S, et al. Relationship between lifestyle factors and hypertension: a cross-sectional analysis from the gubbio study. Acta Cardiol. 2023;78(5):565–573. doi: 10.1080/00015385.2022.2088170.
  • Vynckier P, De Sutter J, De Pauw M, et al. Gender differences in risk factor management and pharmacological treatment among CHD patients: belgian results of the EUROASPIRE IV and EUROASPIRE V surveys. Acta Cardiol. 2023;78(5):607–613. doi: 10.1080/00015385.2023.2169439.
  • Şaylık F, Akbulut T. Temporal relationship between serum calcium and triglyceride-glucose index and its impact on the incident of the acute coronary syndrome: a cross-lagged panel study. Acta Cardiol. 2023;78(5):586–593. doi: 10.1080/00015385.2022.2106017.
  • Li H, Wei Y, Xi Y, et al. DR1-CSE/H2S pathway upregulates autophagy and inhibits H9C2 cells damage induced by high glucose. Acta Cardiol. 2023;78(5):594–606. doi: 10.1080/00015385.2022.2119663.
  • Cheng X, Li Z, Yang M, et al. Association of HbA1c with carotid artery plaques in patients with coronary heart disease. Acta Cardiol. 2022;31:1–9.
  • Sprynger M, Lancellotti P. Comments on association of HbA1c with carotid artery plaques in patients with coronary heart disease. Acta Cardiol. 2023;78(5):635–636.
  • Krohn JB, Neubauer C, Fischer S, et al. Optimisation of individual cardiovascular risk assessment in a german coronary artery disease cohort using a commercial test for genetic polymorphisms - a pilot study. Acta Cardiol. 2022;3:1–11.
  • Mungmunpuntipantip R, Wiwanitkit V. Comment on optimisation of individual cardiovascular risk assessment using a commercial test for genetic polymorphisms. Acta Cardiol. 2023;78(5):634. doi: 10.1080/00015385.2022.2135239.
  • Deconinck A, Morra S, Glassée N, et al. Value of repeated measurements of lipoprotein (a) to assess cardiovascular risk: a retrospective study. Acta Cardiol. 2023;78(5):536–542. doi: 10.1080/00015385.2022.2031377.
  • van de Borne P, Peeters A, Leone A, et al. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiol. 2022;20:1–10. doi: 10.1080/00015385.2022.2030568.
  • Martens P, Mathieu C, Vanassche T. The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiol. 2023;78(5):552–564. doi: 10.1080/00015385.2022.2076307.
  • Boulmpou A, Patoulias D, Papadopoulos CE, et al. Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. Acta Cardiol. 2023;78(5):519–524. doi: 10.1080/00015385.2022.2087839.
  • Nagarajan G, Govindan R, Poomarimuthu M, et al. The microbiome and rheumatic heart disease: current knowledge and future perspectives. Acta Cardiol. 2023;78(5):525–533. doi: 10.1080/00015385.2023.2207933.
  • Köseoğlu C, Ramazan Öncel C. Possible effects of subclinical hypothyroidism on right ventricular myocardial work parameters. Acta Cardiol. 2023;78(5):637. doi: 10.1080/00015385.2023.2214405.
  • Yurdam FS, Gürses E. Myocardial bridge and beta blockers: effect on left ventricular strain parameters. Acta Cardiol. 2023;78(5):623–629. doi: 10.1080/00015385.2023.2209421.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.